文献速递冠心病

过去20年STEMI患者预后改善与循证治疗实施相关:SWEDEHEART注册研究1995-2014

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
PubMed 文献 · Eur Heart J · 2017-01-01

结果显示再灌注、直接PCI、双联抗血小板、他汀等循证治疗使用率显著增加,1年死亡率从22.1%降至14.1%,心血管死亡、心梗、卒中、心衰均下降;校正治疗变化后,1年心血管死亡或心梗的线性趋势不再显著。

要点

  • 循证治疗(再灌注、直接PCI、双联抗血小板、他汀等)使用率显著增加,趋势P<0.001。
  • 1年死亡率从22.1%降至14.1%,心血管死亡从20.1%降至11.1%。
  • 校正治疗变化后,1年心血管死亡或心梗的改善趋势不再显著。

核心结论

  • 过去20年STEMI患者循证治疗的逐步实施与生存延长和复发缺血事件风险降低相关,但2008年左右起改善趋于平台。

主要发现

  • 再灌注率从66.2%增至81.7%,直接PCI从4.5%增至78.0%,双联抗血小板从0增至89.6%,他汀从14.1%增至93.6%,β受体阻滞剂从78.2%增至91.0%,ACEI/ARB从40.8%增至85.2%(趋势P<0.001)。
  • 1年死亡率从22.1%降至14.1%,标准化发病比从5.54降至3.74(P<0.001)。
  • 心血管死亡从20.1%降至11.1%,心肌梗死从11.5%降至5.8%,卒中从2.9%降至2.1%,心衰从7.1%降至6.2%。
  • 校正人口学和基线特征后,1年心血管死亡或心梗每2年线性趋势为0.915(95%CI 0.906-0.923),进一步校正治疗变化后为0.997(95%CI 0.984-1.009),不再显著。
  • 治疗和结局的变化在1994至2008年最为明显。

临床怎么用

  • 应持续推动STEMI患者循证治疗(再灌注、直接PCI、双联抗血小板、他汀、β受体阻滞剂、ACEI/ARB)的规范实施。
  • 2008年后预后改善趋缓,需关注进一步优化治疗实施和探索新的改善策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Impact of changes of treatments on outcomes in ST-elevation myocardial infarction (STEMI) patients in real-life health care has not been documented. METHODS AND RESULTS: All STEMI cases (n = 105.674) registered in the nation-wide SWEDEHEART registry between 1995 and 2014 were included and followed for fatal and non-fatal outcomes for up to 20 years. Most changes in treatment and outcomes occurred from 1994 to 2008. Evidence-based treatments increased: reperfusion from 66.2 to 81.7%; primary percutaneous coronary intervention: 4.5 to 78.0%; dual antiplatelet therapy from 0 to 89.6%; statin: 14.1 to 93.6%; beta-blocker: 78.2 to 91.0%, and angiotensin-converting-enzyme/angiotensin-2-receptor inhibitors: 40.8 to 85.2% (P-value for-trend <0.001 for all). One-year mortality decreased from 22.1 to 14.1%. Standardized incidence ratio compared with the general population decreased from 5.54 to 3.74 (P < 0.001). Cardiovascular (CV) death decreased from 20.1 to 11.1%, myocardial infarction (MI) from 11.5 to 5.8%; stroke from 2.9 to 2.1%; heart failure from 7.1 to 6.2%. After standardization for differences in demography and baseline characteristics, the change of 1-year CV-death or MI corresponded to a linear trend of 0.915 (95% confidence interval: 0.906-0.923) per 2-year period which no longer was significant, 0.997 (0.984-1.009), after adjustment for changes in treatment. The changes in treatment and outcomes were most pronounced from 1994 to 2008. CONCLUSION: Gradual implementation of new and established evidence-based treatments in STEMI patients during the last 20 years has been associated with prolonged survival and lower risk of recurrent ischaemic events, although a plateauing is seen since around 2008.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017. PMID: 29020314. doi:10.1093/eurheartj/ehx515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。